What they were paid
CRISPR Therapeutics Director Compensation Table · all 5 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $78,177 | — | $285,740 | $0 | $363,917 |
| FY2024 | $75,426 | $0 | $409,680 | $0 | $485,106 |
| FY2023 | $72,500 | $0 | $482,560 | $0 | $555,060 |
| FY2022 | $72,500 | $0 | $548,431 | $0 | $620,931 |
| FY2021 | $64,709 | $0 | $752,798 | $0 | $817,507 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRISPR Therapeutics AG DEF 14A filed April 21, 2026, accession 0001193125-26-165158, and prior-year filings. Open the filing on EDGAR.
How this page was built: the CRISPR Therapeutics AG filed document, accession 0001193125-26-165158. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.
Get the CRISPR Therapeutics Board Governance Report
$363,917 John T. Greene, FY2025 total director compensation
$500
The free page is the headline figures. The board report is director pay, board composition and committee fees combined into the same kind of document.
Data as of April 21, 2026 · Source: Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
How this board is paid
company policy · FY2025CRISPR Therapeutics pays directors a $50,000 cash retainer and $285,740 in Options.
Committees
FY2025 · as the proxy prints themAudit (Chair) · Compensation · Nominating/Governance
The rest of the CRISPR Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Ali Behbahani | Independent Director | $348,240 |
| Briggs W. Morrison | Independent Director | $341,069 |
| Christian Rommel | Independent Director | $335,740 |
| Douglas A. Treco | Independent Director | $370,740 |
| H. Edward Fleming Jr | Independent Director | $343,354 |
| Katherine A. High | Independent Director | $358,123 |
| Maria Fardis | Independent Director | $349,715 |
| Samarth Kulkarni | Chair of the Board | — |
| Sandesh Mahatme | Independent Director | $353,127 |
| Simeon J. George | Independent Director | $342,168 |
The full CRISPR Therapeutics compensation record
free company briefThis page is one director within CRISPR Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Peer companies
named in the CRISPR Therapeutics proxy · each links to its own free briefOrder CRSP
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.